FATE Quote, Trading Chart, Fate Therapeutics Inc.
home / stock / fate / fate quote
$89.72 Last:
4.0% Change Percent:
$88.67 Open:
$89.72 Previous Close:
$93.285 High:
$84.02 Low:
1,195,120 Volume:
02/26/2021 04:55:33 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-26 | 88.67 | 89.72 | 93.285 | 84.02 | 1,195,120 |
| 2021-02-25 | 97.6 | 86.27 | 100.74 | 85.72 | 1,243,453 |
| 2021-02-24 | 96.82 | 95.27 | 98.9688 | 92.501 | 695,010 |
| 2021-02-23 | 96.68 | 95.48 | 98.33 | 87.12 | 1,698,835 |
| 2021-02-22 | 107.73 | 100.96 | 108.03 | 100.01 | 1,183,549 |
| 2021-02-19 | 103.61 | 110.18 | 118.14 | 103.5 | 1,542,635 |
| 2021-02-18 | 100.51 | 102.1 | 103.8 | 98.4 | 828,123 |
| 2021-02-17 | 102.02 | 103.22 | 104.09 | 96.43 | 982,961 |
| 2021-02-16 | 104.5 | 101.44 | 107.43 | 100.71 | 624,923 |
| 2021-02-15 | 100.66 | 102.45 | 103.64 | 98.88 | 587,875 |
| 2021-02-12 | 100.66 | 102.45 | 103.64 | 98.88 | 586,826 |
| 2021-02-11 | 105.14 | 102.5 | 107.76 | 101.83 | 805,896 |
| 2021-02-10 | 106.17 | 103.31 | 109.59 | 100.37 | 626,521 |
| 2021-02-09 | 108.2 | 105.32 | 109.2875 | 104.39 | 510,760 |
| 2021-02-08 | 105.74 | 108.5 | 109.96 | 104.96 | 693,909 |
| 2021-02-05 | 104.97 | 105.19 | 107.3 | 102.19 | 558,571 |
| 2021-02-04 | 100.69 | 102.62 | 104.99 | 99.51 | 623,546 |
| 2021-02-03 | 99.2 | 98.24 | 102.62 | 97.0291 | 827,112 |
| 2021-02-02 | 96 | 97.49 | 100.32 | 95 | 916,582 |
| 2021-02-01 | 91.71 | 93.16 | 94.45 | 90.25 | 914,858 |
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
Image source: The Motley Fool. Fate Therapeutics Inc (NASDAQ: FATE) Q4 2020 Earnings Call Feb 24, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript
-
Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Re...
-
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced t...